Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth Rate by Type: 2018 VS 2022 VS 2033
1.2.2 Real-Time PCR (q-PCR)
1.2.3 Immunohistochemistry (IHC)
1.2.4 Next-Generation Sequencing (NGS)
1.2.5 Fluorescent In-Situ Hybridization (FISH)
1.3 Market by Application
1.3.1 Global Next-Generation Breast Cancer Diagnostic and Screening Market Growth by Application: 2018 VS 2022 VS 2033
1.3.2 Hospital-associated Labs
1.3.3 Cancer Research Institutes
1.3.4 Diagnostic Centers
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Next-Generation Breast Cancer Diagnostic and Screening Market Perspective (2018-2033)
2.2 Next-Generation Breast Cancer Diagnostic and Screening Growth Trends by Region
2.2.1 Global Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Next-Generation Breast Cancer Diagnostic and Screening Historic Market Size by Region (2018-2023)
2.2.3 Next-Generation Breast Cancer Diagnostic and Screening Forecasted Market Size by Region (2024-2033)
2.3 Next-Generation Breast Cancer Diagnostic and Screening Market Dynamics
2.3.1 Next-Generation Breast Cancer Diagnostic and Screening Industry Trends
2.3.2 Next-Generation Breast Cancer Diagnostic and Screening Market Drivers
2.3.3 Next-Generation Breast Cancer Diagnostic and Screening Market Challenges
2.3.4 Next-Generation Breast Cancer Diagnostic and Screening Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Next-Generation Breast Cancer Diagnostic and Screening Players by Revenue
3.1.1 Global Top Next-Generation Breast Cancer Diagnostic and Screening Players by Revenue (2018-2023)
3.1.2 Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Players (2018-2023)
3.2 Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Next-Generation Breast Cancer Diagnostic and Screening Revenue
3.4 Global Next-Generation Breast Cancer Diagnostic and Screening Market Concentration Ratio
3.4.1 Global Next-Generation Breast Cancer Diagnostic and Screening Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Next-Generation Breast Cancer Diagnostic and Screening Revenue in 2022
3.5 Next-Generation Breast Cancer Diagnostic and Screening Key Players Head office and Area Served
3.6 Key Players Next-Generation Breast Cancer Diagnostic and Screening Product Solution and Service
3.7 Date of Enter into Next-Generation Breast Cancer Diagnostic and Screening Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Next-Generation Breast Cancer Diagnostic and Screening Breakdown Data by Type
4.1 Global Next-Generation Breast Cancer Diagnostic and Screening Historic Market Size by Type (2018-2023)
4.2 Global Next-Generation Breast Cancer Diagnostic and Screening Forecasted Market Size by Type (2024-2033)
5 Next-Generation Breast Cancer Diagnostic and Screening Breakdown Data by Application
5.1 Global Next-Generation Breast Cancer Diagnostic and Screening Historic Market Size by Application (2018-2023)
5.2 Global Next-Generation Breast Cancer Diagnostic and Screening Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size (2018-2033)
6.2 North America Next-Generation Breast Cancer Diagnostic and Screening Market Growth Rate by Country: 2018 VS 2022 VS 2033
6.3 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2018-2023)
6.4 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2024-2033)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size (2018-2033)
7.2 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Growth Rate by Country: 2018 VS 2022 VS 2033
7.3 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2018-2023)
7.4 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2024-2033)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size (2018-2033)
8.2 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Growth Rate by Region: 2018 VS 2022 VS 2033
8.3 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region (2018-2023)
8.4 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region (2024-2033)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size (2018-2033)
9.2 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Growth Rate by Country: 2018 VS 2022 VS 2033
9.3 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2018-2023)
9.4 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2024-2033)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size (2018-2033)
10.2 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Growth Rate by Country: 2018 VS 2022 VS 2033
10.3 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2018-2023)
10.4 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2024-2033)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Abbott Laboratories
11.1.1 Abbott Laboratories Company Detail
11.1.2 Abbott Laboratories Business Overview
11.1.3 Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.1.4 Abbott Laboratories Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)
11.1.5 Abbott Laboratories Recent Development
11.2 Agendia
11.2.1 Agendia Company Detail
11.2.2 Agendia Business Overview
11.2.3 Agendia Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.2.4 Agendia Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)
11.2.5 Agendia Recent Development
11.3 Agilent Technologies
11.3.1 Agilent Technologies Company Detail
11.3.2 Agilent Technologies Business Overview
11.3.3 Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.3.4 Agilent Technologies Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)
11.3.5 Agilent Technologies Recent Development
11.4 Ambry Genetics
11.4.1 Ambry Genetics Company Detail
11.4.2 Ambry Genetics Business Overview
11.4.3 Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.4.4 Ambry Genetics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)
11.4.5 Ambry Genetics Recent Development
11.5 Biocept
11.5.1 Biocept Company Detail
11.5.2 Biocept Business Overview
11.5.3 Biocept Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.5.4 Biocept Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)
11.5.5 Biocept Recent Development
11.6 Biotheranostics
11.6.1 Biotheranostics Company Detail
11.6.2 Biotheranostics Business Overview
11.6.3 Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.6.4 Biotheranostics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)
11.6.5 Biotheranostics Recent Development
11.7 Centogene
11.7.1 Centogene Company Detail
11.7.2 Centogene Business Overview
11.7.3 Centogene Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.7.4 Centogene Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)
11.7.5 Centogene Recent Development
11.8 Danaher Corporation
11.8.1 Danaher Corporation Company Detail
11.8.2 Danaher Corporation Business Overview
11.8.3 Danaher Corporation Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.8.4 Danaher Corporation Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)
11.8.5 Danaher Corporation Recent Development
11.9 EXACT Sciences Corporation
11.9.1 EXACT Sciences Corporation Company Detail
11.9.2 EXACT Sciences Corporation Business Overview
11.9.3 EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.9.4 EXACT Sciences Corporation Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)
11.9.5 EXACT Sciences Corporation Recent Development
11.10 Roche Holding AG
11.10.1 Roche Holding AG Company Detail
11.10.2 Roche Holding AG Business Overview
11.10.3 Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.10.4 Roche Holding AG Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)
11.10.5 Roche Holding AG Recent Development
11.11 Fulgent Genetics
11.11.1 Fulgent Genetics Company Detail
11.11.2 Fulgent Genetics Business Overview
11.11.3 Fulgent Genetics Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.11.4 Fulgent Genetics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)
11.11.5 Fulgent Genetics Recent Development
11.12 Illumina
11.12.1 Illumina Company Detail
11.12.2 Illumina Business Overview
11.12.3 Illumina Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.12.4 Illumina Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)
11.12.5 Illumina Recent Development
11.13 Invitae
11.13.1 Invitae Company Detail
11.13.2 Invitae Business Overview
11.13.3 Invitae Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.13.4 Invitae Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)
11.13.5 Invitae Recent Development
11.14 Lucence Diagnostics Pte Ltd
11.14.1 Lucence Diagnostics Pte Ltd Company Detail
11.14.2 Lucence Diagnostics Pte Ltd Business Overview
11.14.3 Lucence Diagnostics Pte Ltd Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.14.4 Lucence Diagnostics Pte Ltd Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)
11.14.5 Lucence Diagnostics Pte Ltd Recent Development
11.15 Myriad Genetics
11.15.1 Myriad Genetics Company Detail
11.15.2 Myriad Genetics Business Overview
11.15.3 Myriad Genetics Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.15.4 Myriad Genetics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)
11.15.5 Myriad Genetics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2033
Table 2. Key Players of Real-Time PCR (q-PCR)
Table 3. Key Players of Immunohistochemistry (IHC)
Table 4. Key Players of Next-Generation Sequencing (NGS)
Table 5. Key Players of Fluorescent In-Situ Hybridization (FISH)
Table 6. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2033
Table 7. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region (US$ Million): 2018 VS 2022 VS 2033
Table 8. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region (2018-2023) & (US$ Million)
Table 9. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Region (2018-2023)
Table 10. Global Next-Generation Breast Cancer Diagnostic and Screening Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 11. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Region (2024-2033)
Table 12. Next-Generation Breast Cancer Diagnostic and Screening Market Trends
Table 13. Next-Generation Breast Cancer Diagnostic and Screening Market Drivers
Table 14. Next-Generation Breast Cancer Diagnostic and Screening Market Challenges
Table 15. Next-Generation Breast Cancer Diagnostic and Screening Market Restraints
Table 16. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue by Players (2018-2023) & (US$ Million)
Table 17. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Players (2018-2023)
Table 18. Global Top Next-Generation Breast Cancer Diagnostic and Screening Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Next-Generation Breast Cancer Diagnostic and Screening as of 2022)
Table 19. Ranking of Global Top Next-Generation Breast Cancer Diagnostic and Screening Companies by Revenue (US$ Million) in 2022
Table 20. Global 5 Largest Players Market Share by Next-Generation Breast Cancer Diagnostic and Screening Revenue (CR5 and HHI) & (2018-2023)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Next-Generation Breast Cancer Diagnostic and Screening Product Solution and Service
Table 23. Date of Enter into Next-Generation Breast Cancer Diagnostic and Screening Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2018-2023) & (US$ Million)
Table 26. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Type (2018-2023)
Table 27. Global Next-Generation Breast Cancer Diagnostic and Screening Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 28. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Type (2024-2033)
Table 29. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2018-2023) & (US$ Million)
Table 30. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Application (2018-2023)
Table 31. Global Next-Generation Breast Cancer Diagnostic and Screening Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 32. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Application (2024-2033)
Table 33. North America Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 34. North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2018-2023) & (US$ Million)
Table 35. North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2024-2033) & (US$ Million)
Table 36. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 37. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2018-2023) & (US$ Million)
Table 38. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2024-2033) & (US$ Million)
Table 39. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2033
Table 40. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region (2018-2023) & (US$ Million)
Table 41. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region (2024-2033) & (US$ Million)
Table 42. Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 43. Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2018-2023) & (US$ Million)
Table 44. Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2024-2033) & (US$ Million)
Table 45. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 46. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2018-2023) & (US$ Million)
Table 47. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2024-2033) & (US$ Million)
Table 48. Abbott Laboratories Company Detail
Table 49. Abbott Laboratories Business Overview
Table 50. Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Product
Table 51. Abbott Laboratories Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) & (US$ Million)
Table 52. Abbott Laboratories Recent Development
Table 53. Agendia Company Detail
Table 54. Agendia Business Overview
Table 55. Agendia Next-Generation Breast Cancer Diagnostic and Screening Product
Table 56. Agendia Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) & (US$ Million)
Table 57. Agendia Recent Development
Table 58. Agilent Technologies Company Detail
Table 59. Agilent Technologies Business Overview
Table 60. Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Product
Table 61. Agilent Technologies Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) & (US$ Million)
Table 62. Agilent Technologies Recent Development
Table 63. Ambry Genetics Company Detail
Table 64. Ambry Genetics Business Overview
Table 65. Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Product
Table 66. Ambry Genetics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) & (US$ Million)
Table 67. Ambry Genetics Recent Development
Table 68. Biocept Company Detail
Table 69. Biocept Business Overview
Table 70. Biocept Next-Generation Breast Cancer Diagnostic and Screening Product
Table 71. Biocept Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) & (US$ Million)
Table 72. Biocept Recent Development
Table 73. Biotheranostics Company Detail
Table 74. Biotheranostics Business Overview
Table 75. Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Product
Table 76. Biotheranostics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) & (US$ Million)
Table 77. Biotheranostics Recent Development
Table 78. Centogene Company Detail
Table 79. Centogene Business Overview
Table 80. Centogene Next-Generation Breast Cancer Diagnostic and Screening Product
Table 81. Centogene Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) & (US$ Million)
Table 82. Centogene Recent Development
Table 83. Danaher Corporation Company Detail
Table 84. Danaher Corporation Business Overview
Table 85. Danaher Corporation Next-Generation Breast Cancer Diagnostic and Screening Product
Table 86. Danaher Corporation Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) & (US$ Million)
Table 87. Danaher Corporation Recent Development
Table 88. EXACT Sciences Corporation Company Detail
Table 89. EXACT Sciences Corporation Business Overview
Table 90. EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Product
Table 91. EXACT Sciences Corporation Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) & (US$ Million)
Table 92. EXACT Sciences Corporation Recent Development
Table 93. Roche Holding AG Company Detail
Table 94. Roche Holding AG Business Overview
Table 95. Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Product
Table 96. Roche Holding AG Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) & (US$ Million)
Table 97. Roche Holding AG Recent Development
Table 98. Fulgent Genetics Company Detail
Table 99. Fulgent Genetics Business Overview
Table 100. Fulgent Genetics Next-Generation Breast Cancer Diagnostic and Screening Product
Table 101. Fulgent Genetics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) & (US$ Million)
Table 102. Fulgent Genetics Recent Development
Table 103. Illumina Company Detail
Table 104. Illumina Business Overview
Table 105. Illumina Next-Generation Breast Cancer Diagnostic and Screening Product
Table 106. Illumina Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) & (US$ Million)
Table 107. Illumina Recent Development
Table 108. Invitae Company Detail
Table 109. Invitae Business Overview
Table 110. Invitae Next-Generation Breast Cancer Diagnostic and Screening Product
Table 111. Invitae Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) & (US$ Million)
Table 112. Invitae Recent Development
Table 113. Lucence Diagnostics Pte Ltd Company Detail
Table 114. Lucence Diagnostics Pte Ltd Business Overview
Table 115. Lucence Diagnostics Pte Ltd Next-Generation Breast Cancer Diagnostic and Screening Product
Table 116. Lucence Diagnostics Pte Ltd Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) & (US$ Million)
Table 117. Lucence Diagnostics Pte Ltd Recent Development
Table 118. Myriad Genetics Company Detail
Table 119. Myriad Genetics Business Overview
Table 120. Myriad Genetics Next-Generation Breast Cancer Diagnostic and Screening Product
Table 121. Myriad Genetics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) & (US$ Million)
Table 122. Myriad Genetics Recent Development
Table 123. Research Programs/Design for This Report
Table 124. Key Data Information from Secondary Sources
Table 125. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size Comparison by Type (2023-2033) & (US$ Million)
Figure 2. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Type: 2022 VS 2033
Figure 3. Real-Time PCR (q-PCR) Features
Figure 4. Immunohistochemistry (IHC) Features
Figure 5. Next-Generation Sequencing (NGS) Features
Figure 6. Fluorescent In-Situ Hybridization (FISH) Features
Figure 7. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size Comparison by Application (2023-2033) & (US$ Million)
Figure 8. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Application: 2022 VS 2033
Figure 9. Hospital-associated Labs Case Studies
Figure 10. Cancer Research Institutes Case Studies
Figure 11. Diagnostic Centers Case Studies
Figure 12. Next-Generation Breast Cancer Diagnostic and Screening Report Years Considered
Figure 13. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 14. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 15. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Region: 2022 VS 2033
Figure 16. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Players in 2022
Figure 17. Global Top Next-Generation Breast Cancer Diagnostic and Screening Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Next-Generation Breast Cancer Diagnostic and Screening as of 2022)
Figure 18. The Top 10 and 5 Players Market Share by Next-Generation Breast Cancer Diagnostic and Screening Revenue in 2022
Figure 19. North America Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 20. North America Next-Generation Breast Cancer Diagnostic and Screening Market Share by Country (2018-2033)
Figure 21. United States Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 22. Canada Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 23. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 24. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Share by Country (2018-2033)
Figure 25. Germany Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 26. France Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 27. U.K. Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 28. Italy Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. Russia Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. Nordic Countries Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 31. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Share by Region (2018-2033)
Figure 33. China Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 34. Japan Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. South Korea Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. Southeast Asia Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 37. India Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 38. Australia Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 39. Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 40. Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Share by Country (2018-2033)
Figure 41. Mexico Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 42. Brazil Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 43. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Share by Country (2018-2033)
Figure 45. Turkey Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 46. Saudi Arabia Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 47. Abbott Laboratories Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)
Figure 48. Agendia Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)
Figure 49. Agilent Technologies Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)
Figure 50. Ambry Genetics Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)
Figure 51. Biocept Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)
Figure 52. Biotheranostics Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)
Figure 53. Centogene Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)
Figure 54. Danaher Corporation Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)
Figure 55. EXACT Sciences Corporation Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)
Figure 56. Roche Holding AG Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)
Figure 57. Fulgent Genetics Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)
Figure 58. Illumina Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)
Figure 59. Invitae Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)
Figure 60. Lucence Diagnostics Pte Ltd Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)
Figure 61. Myriad Genetics Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed